just as it was in the testing for ruxo, with MF, the outcome will be more than likely be approved for severe cases, and to those intolerant to HU. So it is asked why then is this hurting the stock? A couple of reason come to mind, the stock is still trading in a death cross pattern, secondly it is a phase III trial that missed on endpoints. What management was trying to do here, after hopeful approval from the FDA, was to say again to the fda look at the RELIEF study it works on the MILD PV cases. How much money and works have been spent, and now it is another phase 2 or 3 trial to go back and see if they can still get it approved for mild PV. DID not INcyte go all through this once already in the approval for MF, the answer is yes, so why did they think it would now work for PV???? They sure presented to investors that they thought it would be? I think that pretty much gives you why it will be down. oh, the ceo says it is undervalued in the 60's, insiders have sold massive amounts of holdings....earnings will be a miss, and oh how nice it is to hear the sNDA has been filed on a PHASE 3 (RELIEF) missing its ENDPOINTS, good use of PR
it should not matter if one is long or short, ALL SHOULD BE ANNOYED WITH HERVE"S COMMENTS, PAUL WOULD NOT HAVE SAID THIS! A ceo should lead by actions not comments, if you say something is undervalued or overvalued , then buy or sell accordingly, do not have the whole management team , selling while you are PUMPING. Just the same for Janet Yellen, she as the head of the fed revserve has no place talking BUBBLES in bio tech and social media, when you have one the fed has created (Big Ben)
you are a pos, i do not care if every insider sold everything on a planned sale or not, did they EVER BUY ANY, NO, is it a sale YES........................HOPPENOT can go on BLOOMBERG TV and say the shares are UNDERVALUED, in the same week 6 insiders are selling, and the stock is not anywhere near the 64 when the ceo was pumping it........YOU ARE A WORTHLESS piece of humanity, and since you can add nothing but attack me guess i need to post MORE NOW
something to chew on, nvs growth is different than incy, as they continue to have jakavi available in more countries, incy, does not
your past tack record as i recall is far from accurate, with you being as much as 10 million over, and you have also used the inventory adjustment before as well, if sales are above 80 million i will be surprised, and i see off label growing to 15%, no reason it will go down
lets see 70 to 90 that is just under 30% sales increase if you say 96 that is 37%, so with most of the growth in past eight 8q averaging APPROXIMATELY10%, explain how you get 30% or MORE,
look at rsi, during the last dip to 40, then look at the macd, 50 crossing under 200
MArket condions are interesting, very BEARISH on the stock value and could turn for the overall market as well, but the micro i believe has little effect on sales.
Your comments are sound in regards to sales, as you know from all my past estimates, I have done ok. I usually do not look out past present q's as I refigure my estimates at the end of each q..
1) move up on the russell 1000, on the last day of june no effect
2) incyte milestone payment,of 60 million, did not happen
3) incyte announces sNDA filing, did not happen as they told everyone it would before the end of 2q, though possibly it could be, but why all the secrets, did you NOT learn with the ASCO debacle ??????????
may 14 incyte was mid 58, 5 trading days later may 21 it was mid 46's, no bounce today so we need to look back FURTHER that is April 15 with the low of 40.30, i was wrong in that i thought 44 was pre asco low,, but since incyte plunged right through the the 46s , lots of red can head the longs direction, considering also the death cross is here
okay, since you asked, Incyte does not as of yet, beat their own estimates. they said 315 t0 335 for 2014. they had 70 in q1 so i gave them their largest growth in q2, that getting sales of 80, then 85 in 3q and 90 in q4 , all said that comes in at 325, smack in the middle of estimates, contract slaers, 10 million and I am probably low on royality as it is 13, to 14 m based on nvs sales
lets see what 500, 700, 1000 points does then, hope your eyes are open now !!!!!!
iam not saying i am right after the effect, but go back and look at my posts in the first week of july, in them i point out how incyte started trading opposite to the indexes of , ibb, fbt, bib. someone posted long ago that incyte trading in tandem it was either, pharm or medx
the downward pressure on incyte